Avenue Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Tables)

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of diluted income (loss) per share

The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented:


	For the Years Ended
	December 31,	December 31,
	2019	2018
Restricted stock units/awards	1,045,162	1,104,643
Preferred shares	250,000	250,000
Options	—	20,000
Total potential dilutive effect	1,295,162	1,374,643